The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by Wenzhou Medical University.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
JiFei Tang, Wenzhou Medical College
ClinicalTrials.gov Identifier:
NCT01750502
First received: November 24, 2012
Last updated: June 14, 2013
Last verified: May 2012
  Purpose

Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that promote the inflammatory response.In animal studies, it has been found that MIF is released in the ischaemic heart, promoting glucose uptake and protecting the heart from ischaemia-reperfusion injury.The MIF concentration, influenced by age and myocardial ischemia, have different impact on myocardial functional recovery after ischemia.Therefore, the purpose of this experiment is to study the clinical significance of MIF in patients with coronary heart disease.


Condition
Coronary Heart Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: MIF Gene Polymorphism in Coronary Heart Disease:Clinical Meaning

Resource links provided by NLM:


Further study details as provided by Wenzhou Medical University:

Primary Outcome Measures:
  • Comparison between coronary-artery-disease group and non-coronary-artery-disease group on MIF concentration [ Time Frame: Before surgery 5 minutes ] [ Designated as safety issue: Yes ]
    Participants will be extracted 3ml blood before surgery 5 minutes,detection MIF concentration on two groups.The experimental group will be higher than control group.


Secondary Outcome Measures:
  • Comparison the change of MIF before and after PCI at the patients who are acute coronary syndromes and stable ischemic heart disease [ Time Frame: 3 times including before surgery 5 minutes, 5 minutes after the opening of the balloon and after surgery 5 minutes ] [ Designated as safety issue: Yes ]
    PCI are extracted 3 times including before suergery 5 minutes , 5 minutes after the opening of the balloon and after surgery 5 minutes ,and detection MIF concentration .


Biospecimen Retention:   Samples Without DNA

The biospecimen is blood that taken from cubital vein.


Estimated Enrollment: 336
Study Start Date: May 2012
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
coronary-artery-disease group
Participants, who are diagnosed as coronary-artery-disease which including acute coronary syndromes and stable ischemic heart disease, will receive at least one stent.
non-coronary-artery-disease group
Participants, who are diagnosed as non-coronary-artery-disease without acute coronary syndromes and stable ischemic heart disease, will not receive stent.

Detailed Description:

MIF is a pleiotropic cytokine that promote the inflammatory response. MIF is expressed in several cell types,including monocytes/macrophages, vascular smooth muscle and cardiomyocytes, and is released on stimulation from pre-formed storage pools. A foreign study reported that MIF had demonstrated to offer protection from I/R-injury by activating adenosine monophosphate-activated protein kinase (AMPK) and inhibiting c-Jun Nterminal kinase (JNK)-induced apoptosis of cardiomyocytes. In addition, animal experiments showed that MIF was reduced in aged heart compared with young heart. Coronary heart disease is a chronic ischemic disease, in which MIF may play as a protective factor during the whole procedure.

We observed individuals who will be taking coronary angiography during the hospitalization. Individuals will be assigned to coronary-artery-disease group, which included acute coronary syndromes and stable ischemic heart disease, or non-coronary-artery-disease group, according to coronary angiography. All participants will be extracted 3ml blood sample 5 minutes before coronary angiography. Coronary-artery-disease group will be taken another two blood samples, 5 minutes after the opening of the balloon and 5 minutes after the stents have been implanted, respectively.

  Eligibility

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Second Hispital of Wenzhou Medical College outpatient and inpatient

Criteria

Inclusion Criteria:

Control group:

  1. enroll individuals who confirmed by coronary angiography without coronary heart
  2. The age between 20 and 80 years old.
  3. Alanine aminotransferase(ALT):10-55U/L, Aspartate aminotransferase(AST):0-60U/L
  4. Glucose(GLU-S):3.9-6.1mmol/L
  5. Triglycerides(TRIG):0.56-1.7mmol/L, cholesterol(CHOL):3.1-5.2mmol/L, High density lipoprotein(HDL):0.78-1.96mmol/L, High density lipoprotein(LDL):2.07-3.1mmol/L

Experimental group:

  1. enroll individuals who confirmed by coronary angiography for coronary heart
  2. The age between 20 and 80 years old.
  3. ALT:10-55U/L,AST:0-60U/L
  4. GLU-S:3.9-6.1mmol/L
  5. TRIG:0.56-1.7mmol/L,CHOL:3.1-5.2mmol/L,HDL:0.78-1.96mmol/L,LDL:2.07-3.1mmol/L

Exclusion Criteria:

  1. Inflammatory diseases,such as rheumatoid arthritis,sepsis,asthma and acute respiratory distress syndrome.
  2. Diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01750502

Contacts
Contact: JiFei Tang, Master 13676587343 454725192@qq.com

Locations
China, Zhejiang
Second Hispital of Wenzhou Medical College Recruiting
Wenzhou, Zhejiang, China, 325000
Contact: JiFei Tang, MD    13676587343    454725192@qq.com   
Contact: Kangting Ji, MD    13676403180    heywyi@163.com   
Sponsors and Collaborators
Wenzhou Medical University
Investigators
Principal Investigator: Jifei Tang, MD Wenzhou Medical University
  More Information

No publications provided

Responsible Party: JiFei Tang, Director, Wenzhou Medical College
ClinicalTrials.gov Identifier: NCT01750502     History of Changes
Other Study ID Numbers: wenzhouhp
Study First Received: November 24, 2012
Last Updated: June 14, 2013
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on July 26, 2014